These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30993551)

  • 1. Inhibitory Effect of Vonoprazan on the Metabolism of [
    Nishihara M
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):713-717. PubMed ID: 30993551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel.
    Nishihara M; Yamasaki H; Czerniak R; Jenkins H
    Eur J Drug Metab Pharmacokinet; 2019 Apr; 44(2):217-227. PubMed ID: 30361928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype.
    Kagami T; Yamade M; Suzuki T; Uotani T; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Clin Pharmacol Ther; 2018 May; 103(5):906-913. PubMed ID: 28875498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias WL; Braunwald E; Sabatine MS
    Circulation; 2009 May; 119(19):2553-60. PubMed ID: 19414633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro.
    Abell LM; Liu EC
    J Pharmacol Exp Ther; 2011 Nov; 339(2):589-96. PubMed ID: 21828263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.
    Chen CH; Yang JC; Uang YS; Lin CJ
    Biopharm Drug Dispos; 2012 Jul; 33(5):278-83. PubMed ID: 22623337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.
    Rehmel JL; Eckstein JA; Farid NA; Heim JB; Kasper SC; Kurihara A; Wrighton SA; Ring BJ
    Drug Metab Dispos; 2006 Apr; 34(4):600-7. PubMed ID: 16415119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP-Mediated Drug-Drug Interaction Is Not a Major Determinant of Attenuation of Antiplatelet Function of Clopidogrel by Vonoprazan.
    Nishihara M; Czerniak R
    Clin Pharmacol Ther; 2018 Jul; 104(1):31-32. PubMed ID: 29603200
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
    Farid NA; Kurihara A; Wrighton SA
    J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to "CYP-Mediated Drug-Drug Interaction Is Not a Major Determinant of Attenuation of Antiplatelet Function of Clopidogrel by Vonoprazan".
    Kagami T; Furuta T
    Clin Pharmacol Ther; 2018 Jul; 104(1):33-34. PubMed ID: 29663346
    [No Abstract]   [Full Text] [Related]  

  • 11. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.
    Hagihara K; Kazui M; Kurihara A; Yoshiike M; Honda K; Okazaki O; Farid NA; Ikeda T
    Drug Metab Dispos; 2009 Nov; 37(11):2145-52. PubMed ID: 19704027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.
    Ancrenaz V; Daali Y; Fontana P; Besson M; Samer C; Dayer P; Desmeules J
    Curr Drug Metab; 2010 Oct; 11(8):667-77. PubMed ID: 20942779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel.
    Kitazono T; Ikeda Y; Nishikawa M; Yoshiba S; Abe K; Ogawa A
    J Thromb Thrombolysis; 2018 Nov; 46(4):488-495. PubMed ID: 30074128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
    Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
    Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.
    Hagihara K; Nishiya Y; Kurihara A; Kazui M; Farid NA; Ikeda T
    Drug Metab Pharmacokinet; 2008; 23(6):412-20. PubMed ID: 19122335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers.
    Funakoshi R; Tomoda Y; Kudo T; Furihata K; Kusuhara H; Ito K
    Br J Clin Pharmacol; 2019 Jul; 85(7):1454-1463. PubMed ID: 30845361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.
    Nishiya Y; Hagihara K; Kurihara A; Okudaira N; Farid NA; Okazaki O; Ikeda T
    Xenobiotica; 2009 Nov; 39(11):836-43. PubMed ID: 19845434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
    Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
    J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
    Echizen H
    Clin Pharmacokinet; 2016 Apr; 55(4):409-18. PubMed ID: 26369775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.